From: Inadequate reporting quality of registered genome editing trials: an observational study
Genome editing characteristics | No. (%) of trials |
---|---|
Platform: | |
ZFN | 17 (21.0) |
TALENa | 1 (1.2) |
CRISPR/Cas9 | 29 (35.8) |
TALEN and CRISPR/Cas9b | 1 (1.2) |
Not stated | 33 (40.7) |
Testing method: | |
In vivoc | 9 (11.1) |
Ex vivo | 72 (88.9) |
Disease applications: | |
HIV infection and AIDS | 12 (14.8) |
Neoplasms | 57 (70.4) |
Hematological disordersd | 8 (9.9) |
Metabolic diseasese | 2 (2.5) |
Eye diseasesf | 2 (2.5) |
Edited cells: | |
T cellsg | 24 (29.6) |
CAR T cells | 37 (45.7) |
Tumor infiltrating lymphocytes | 2 (2.5) |
Stem or progenitor cellsh | 8 (9.9) |
Hepatocytes | 3 (3.7) |
Epithelial cells | 3 (3.7) |
Human embryosi | 1 (1.2) |
Not stated | 3 (3.7) |
Delivery: | |
Adenovirus | 1 (1.2) |
AAV | 4 (4.9) |
Lentivirus | 2 (2.5) |
Lentiviral and electroporation | 3 (3.7) |
Plasmid | 1 (1.2) |
mRNA | 4 (4.9) |
Intratumoral injection | 1 (1.2) |
Not stated | 65 (80.2) |